Colección SciELO Chile

Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Búsqueda Publicación
Búsqueda por Tema Título, Abstract y Keywords



The Latin American experience with a next generation sequencing genetic panel for recessive limb-girdle muscular weakness and Pompe disease
Indexado
WoS WOS:000513831300001
Scopus SCOPUS_ID:85077786132
DOI 10.1186/S13023-019-1291-2
Año 2020
Tipo artículo de investigación

Citas Totales

Autores Afiliación Chile

Instituciones Chile

% Participación
Internacional

Autores
Afiliación Extranjera

Instituciones
Extranjeras


Abstract



Background Limb-girdle muscular dystrophy (LGMD) is a group of neuromuscular disorders of heterogeneous genetic etiology with more than 30 directly related genes. LGMD is characterized by progressive muscle weakness involving the shoulder and pelvic girdles. An important differential diagnosis among patients presenting with proximal muscle weakness (PMW) is late-onset Pompe disease (LOPD), a rare neuromuscular glycogen storage disorder, which often presents with early respiratory insufficiency in addition to PMW. Patients with PMW, with or without respiratory symptoms, were included in this study of Latin American patients to evaluate the profile of variants for the included genes related to LGMD recessive (R) and LOPD and the frequency of variants in each gene among this patient population. Results Over 20 institutions across Latin America (Brazil, Argentina, Peru, Ecuador, Mexico, and Chile) enrolled 2103 individuals during 2016 and 2017. Nine autosomal recessive LGMDs and Pompe disease were investigated in a 10-gene panel (ANO5, CAPN3, DYSF, FKRP, GAA, SGCA, SGCB, SGCD, SGCG, TCAP) based on reported disease frequency in Latin America. Sequencing was performed with Illumina's NextSeq500 and variants were classified according to ACMG guidelines; pathogenic and likely pathogenic were treated as one category (P) and variants of unknown significance (VUS) are described. Genetic variants were identified in 55.8% of patients, with 16% receiving a definitive molecular diagnosis; 39.8% had VUS. Nine patients were identified with Pompe disease. Conclusions The results demonstrate the effectiveness of this targeted genetic panel and the importance of including Pompe disease in the differential diagnosis for patients presenting with PMW.

Métricas Externas



PlumX Altmetric Dimensions

Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:

Disciplinas de Investigación



WOS
Genetics & Heredity
Medicine, Research & Experimental
Scopus
Sin Disciplinas
SciELO
Sin Disciplinas

Muestra la distribución de disciplinas para esta publicación.

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.

Colaboración Institucional



Muestra la distribución de colaboración, tanto nacional como extranjera, generada en esta publicación.


Autores - Afiliación



Ord. Autor Género Institución - País
1 BEVILACQUA-RIVAS, JORGE ALFREDO Hombre Universidad de Chile - Chile
CLIN DAVILA - Chile
Hospital Clínico de la Universidad de Chile - Chile
Clínica Dávila - Chile
Hospital Clínico Universidad de Chile - Chile
2 Guecaimburu Ehuletche, Maria del Rosario Mujer UdelaR - Uruguay
Universidad La República - Uruguay
Universidad de la República - Uruguay
3 Perna, Abayuba - UdelaR - Uruguay
Hospital de Clínicas Dr. Manuel Quíntela - Uruguay
Universidad La República - Uruguay
Universidad de la República - Uruguay
4 Dubrovsky, Alberto Hombre Favaloro Fdn - Argentina
Fundacion Favaloro - Argentina
5 Franca, Marcondes C. - Univ Campinas UNICAMP - Brasil
Universidade Estadual de Campinas - Brasil
6 Vargas, Steven Hombre Ctr Neurol & Neurosurg - México
Neurology and Neurosurgery National Institute - México
7 Hegde, Madhuri Mujer PerkinElmer - Estados Unidos
PerkinElmer, Inc. - Estados Unidos
8 Claeys, Kristl Mujer Univ Hosp Leuven - Bélgica
Katholieke Univ Leuven - Bélgica
KU Leuven– University Hospital Leuven - Bélgica
KU Leuven - Bélgica
9 Straub, V. Hombre Newcastle Univ - Reino Unido
Newcastle University, United Kingdom - Reino Unido
University of Newcastle upon Tyne, Faculty of Medical Sciences - Reino Unido
10 Daba, Nadia Mujer Sanofi - Emiratos Árabes Unidos
Sanofi - Países Bajos
Sanofi Pasteur - Emiratos Árabes Unidos
Sanofi S.A. - Francia
11 Faria, Roberta Mujer Sanofi - Brasil
Sanofi Pasteur - Brasil
Sanofi Pasteur - Emiratos Árabes Unidos
12 Periquet, Magali Mujer Sanofi - Países Bajos
Sanofi Genzyme - Países Bajos
Sanofi - Brasil
Sanofi Genzyme - Estados Unidos
13 Sparks, Susan Mujer Sanofi Genzyme - Estados Unidos
Genzyme Corporation - Estados Unidos
Sanofi Genzyme - Países Bajos
14 Thibault, Nathan Hombre Sanofi Genzyme - Estados Unidos
Genzyme Corporation - Estados Unidos
Sanofi Genzyme - Países Bajos
15 Araujo, Roberto Hombre Sanofi Genzyme - Estados Unidos
Genzyme Corporation - Estados Unidos
Sanofi Genzyme - Países Bajos

Muestra la afiliación y género (detectado) para los co-autores de la publicación.

Financiamiento



Fuente
Sanofi Genzyme

Muestra la fuente de financiamiento declarada en la publicación.

Agradecimientos



Agradecimiento
This study was funded by Sanofi Genzyme.
JAB has received lecture fees from Sanofi-Genzyme; MRGE has nothing to disclose; AP has received funding from Sanofi Genzyme; AD has taken part in advisory boards and given lectures for Sanofi Genzyme; MF has taken part in advisory boards and given lectures for Sanofi Genzyme; SV has received grant/ research support, has served as a consultant, and served on the speakers bureau for Sanofi Genzyme; MH has nothing to disclose; KGC received travel and research grant from Sanofi Genzyme, unrelated to this study; VS has received speaker honoraria from Sanofi Genzyme and funding for a collaborative sequencing project unrelated to this study; ND, RF, MP, SS, NT, and RA are employees of Sanofi Genzyme and Sanofi shareholders.

Muestra la fuente de financiamiento declarada en la publicación.